CareDx study links elevated AlloSure Kidney levels to nearly threefold higher risk of adverse graft outcomes
CDNA•A CareDx study linked elevated AlloSure Kidney levels to nearly threefold higher risk of graft loss or declining kidney function in patients with borderline rejection or T-cell-mediated rejection. Other studies found AlloSure-based monitoring reduced biopsies while maintaining similar clinical outcomes, and that rejection prediction remained strong under updated Banff 2024 criteria.
1. Study findings
CareDx is presenting AlloSure Kidney study results at ASN Kidney Week in Denver, October 22-25, 2026. Elevated AlloSure Kidney levels were associated with nearly threefold higher risk of graft loss or declining kidney function in patients with borderline rejection or T-cell-mediated rejection.
2. Additional research
An independent randomized trial found AlloSure-based monitoring reduced kidney transplant biopsies while maintaining similar clinical outcomes. A multinational validation study found AlloSure Kidney and AlloSure Plus maintained strong rejection prediction under updated Banff 2024 pathology criteria.
